权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Dissecting the functional role of LINE1 retrotransposon-mediated interferon signaling in myeloid leukemia

剖析 LINE1 逆转录转座子介导的干扰素信号在髓系白血病中的功能作用

基本信息

批准号：
10536349
负责人：
Michael Lee
金额：
$ 3.77万
依托单位：
UT SOUTHWESTERN MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-07-18 至 2026-07-17
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10536349
关键词：
Ablation Acute Myelocytic Leukemia Address Adult Affect Apoptosis Biology CRISPR-mediated transcriptional activation Cell Aging Cell Cycle Arrest Cell Proliferation Clustered Regularly Interspaced Short Palindromic Repeats Complementary DNA DNA Dependence Development Double-Stranded RNA Elements Epigenetic Process Gene Expression Regulation Genetic Genetic Transcription Genetic study Genome Stability Genomic DNA Hematologic Neoplasms Hematopoiesis Hematopoietic Hematopoietic Neoplasms Human Immune Impairment In Vitro Individual Inflammation Innate Immune Response Interferon Activation Interferon Type I Interferons Jumping Genes Knockout Mice Knowledge Link Long Interspersed Elements MLL-AF9 Maintenance Malignant - descriptor Malignant Neoplasms Mediating Modeling Molecular Mus Myelogenous Myeloid Leukemia Natural Immunity Nature Nucleic Acids Pathogenesis Pathway interactions Patients RNA Reporting Repression Retrotransposition Retrotransposon Reverse Transcription Role Signal Pathway Signal Transduction Survival Rate Therapeutic Transcript Transgenic Mice Viral Work Xenograft procedure acute myeloid leukemia cell base cancer type chemotherapy clinical heterogeneity epigenetic silencing gene product in vivo inhibitor knock-down leukemia leukemia initiating cell leukemogenesis mimicry mouse model mutant novel therapeutics overexpression receptor response self-renewal sensor small hairpin RNA standard of care targeted treatment tumor tumorigenesis

项目摘要

PROJECT SUMMARY Acute myeloid leukemia (AML) is one of the most aggressive hematologic malignancies in adults, yet decades- old chemotherapies remain the standard of care and few targeted therapies exist owing to its molecular and clinical heterogeneity. An emerging hallmark of AML development is the epigenetic silencing of LINE1 retrotransposons which is required to maintain AML self-renewal, differentiation blockade, and genomic stability. Aberrant reactivation of LINE1 retrotransposons selectively impairs propagation of human and mouse AML cells without affecting normal hematopoiesis; however, it remains elusive how LINE1 activity inhibits myeloid leukemogenesis. Aberrant retrotransposon reactivation by cancer-targeting epigenetic inhibitors such as DNA hypomethylating agents (DMA) produces a type I interferon (IFN)-mediated ‘viral mimicry’ response in various cancer types, including leukemias, resulting in cell cycle arrest and apoptosis. We hypothesize that LINE1 retrotransposons contribute to the development of myeloid leukemia by modulating type I interferon signaling mediated by cGAS and/or RIG-I-like Receptor (RLR) sensing of LINE1 gene products. This proposal will establish the functional role of LINE1-mediated IFN signaling in myeloid leukemogenesis and determine the mechanisms by which LINE1 activates innate immune ‘viral mimicry’ pathways in AML cells. The Specific Aims of this proposal intend to 1) establish the functional role of LINE1-mediated interferon signaling in myeloid leukemogenesis and progression; and 2) identify the molecular sensors of LINE1-mediated interferon activation in AML. Ectopic LINE1 overexpression and CRISPR activation of endogenous LINE1s in human AML cells will determine whether LINE1 expression induces type I IFNs and impacts cell proliferation, myeloid differentiation, and/or apoptosis. Combining a conditional LINE1 activation transgenic mouse with the established MLL-AF9 retroviral leukemia model will determine whether activation of LINE1s induces hematopoietic-specific type I IFN to impair AML initiation and/or maintenance in vivo. Moreover, genetic ablation of cGAS, RIG-I, or MDA5 nucleic acid sensors individually or in combination in human AML cells and their corresponding knockout mouse models will determine how loss of DNA- and/or RNA-sensing pathways affects LINE1-induced inflammation and AML pathogenesis in vivo. Altogether, these stringent genetic studies will provide direct evidence to establish the functional role of LINE1-mediated IFN signaling in myeloid leukemia. Addressing these outstanding knowledge gaps will be critical to inform whether and how modulation of the retrotransposon-innate immunity crosstalk may be leveraged as a new mechanism-based therapeutic strategy to selectively eradicate AML cells.

项目总结急性髓系白血病(AML)是成人最具侵袭性的血液系统恶性肿瘤之一，然而几十年来- 旧的化疗仍然是治疗的标准，由于其分子和临床异质性。AML发展的一个新标志是LINE1的表观遗传学沉默逆转座子，这是维持AML自我更新、分化阻断和基因组稳定所必需的。 LINE1反转录转座子的异常激活选择性损害人和小鼠急性髓系白血病细胞的增殖不影响正常的造血；然而，LINE1活性如何抑制髓系仍然难以捉摸白血病的发生。肿瘤靶向表观遗传抑制物如DNA的反转座子异常激活去甲基化药物(DMA)在不同的疾病中产生I型干扰素(干扰素)介导的病毒模仿反应癌症类型，包括白血病，导致细胞周期停滞和细胞凋亡。我们假设LINE1 反转录转座子通过调节I型干扰素信号参与髓系白血病的发展由cGAS和/或RIG-I样受体(RLR)介导的LINE1基因产物的传感。这项提议将建立LINE1介导的干扰素信号在髓系白血病发生中的功能作用 LINE1激活AML细胞中的天然免疫“病毒拟态”途径的机制。具体目标这项建议的目的是：1)确定LINE1介导的干扰素信号在髓系中的功能作用白血病的发生和进展；2)鉴定LINE1介导的干扰素激活的分子传感器在AML中。内源性LINE1s在人AML细胞中的异位过表达和CRISPR激活确定LINE1表达是否诱导I型IFN并影响细胞增殖、髓系分化、和/或细胞凋亡。条件激活LINE1转基因小鼠与已建立的MLL-AF9的结合逆转录病毒白血病模型将决定LINE1s激活是否诱导造血特异性I型干扰素损害AML在体内的启动和/或维持。此外，cGAS、RIG-I或MDA5核的遗传消融人急性髓系白血病细胞及其相应的基因敲除小鼠模型中单独或联合的酸传感器将决定DNA和/或RNA传感通路的缺失如何影响LINE1诱导的炎症和AML 体内致病机制。总之，这些严格的基因研究将提供直接证据，证明 LINE1介导的干扰素信号在髓系白血病中的功能作用解决这些突出的知识间隙对于了解反转录转座子-天然免疫串扰是否以及如何调制将是至关重要的作为一种新的基于机制的治疗策略，选择性地根除AML细胞。